Drug Trial Radar · NCT07249164
Dexmedetomidine Medication Records and Delirium After Coronary Artery Bypass Grafting
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
343,112
Actual
Start
Jan 1, 2010
Primary completion
Jul 31, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- China Medical University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 25, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This retrospective observational study uses de-identified electronic health records from the TriNetX Global Collaborative Network. The procedure eligibility period is 1 January 2010 through 1 July 2025. The primary analysis concerns adults with a recorded qualifying coronary artery bypass grafting (CABG) procedure. Valve-coded procedures are examined in a separately constructed and separately matched exploratory population. The populations may overlap and do not constitute independent replication cohorts. Patients are classified by the presence or absence of a dexmedetomidine medication record on the calendar day before or the day of the index procedure. This definition does not confirm administration, dose or intraday timing. The primary outcome is a qualifying delirium or disorientation code during days 1-30. Nine secondary endpoints concern mortality and selected recorded complications during days 0-30; eight are inferential and the prolonged-ventilation code endpoint is descriptive. An inpatient or observation encounter during days 1-30 is described separately and is not interpreted as readmission. Same-day records cannot establish whether an outcome preceded or followed exposure. No treatment is assigned by the investigators. Analyses use permitted aggregate outputs, without identifiable or row-level participant data. The clinical definitions were revised with knowledge of earlier analyses. CABG primary and F05-only outcomes were first rerun on 5 September 2026 and were seen before a technical amendment permitting automatic propensity-score rematching for each outcome batch and unavoidable comparative calculations accompanying descriptive patient counts. The approved eligibility, exposure and outcome windows, codes, covariates, category boundaries and eight-test multiplicity family were not changed by that technical amendment. Subsequent technical refreshes and their source versions are recorded separately. Neither the original registration nor this amendment is presented as prospective registration of the original analysis. The investigators concluded this registered analysis without publication and do not plan further amendments to this record. A separate analysis under the same ethics approval, using a different network, study period, exposure window and outcome definitions, is being reported independently and is not part of this registration.
Conditions
- Delirium
- Cardiac Surgical Procedures
- Coronary Artery Bypass Graft (CABG)
- Valve Surgery
- Postoperative Complications
Interventions
DexmedetomidineDrug
An observed dexmedetomidine medication record (RxNorm 48937) on the calendar day before or the day of the index procedure. No drug, dose, route or regimen is assigned by the study. This entry describes the record used for exposure classification, not a study intervention.
No dexmedetomidine medication record in the specified windowOther
Absence of a dexmedetomidine medication record during days -1 through 0 relative to the index procedure. Other care is not assigned or standardised by the investigators. Dexmedetomidine records outside the specified window are allowed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- First recorded code-defined delirium or disorientation during days 1-30 after the index procedureTime frame: Day 1 through Day 30 after the index procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China Medical University Hospital
Taichung, Taichung City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.